Biomimetic UHMWPE/HA scaffolds with rhBMP-2 and erythropoietin for reconstructive surgery

Mater Sci Eng C Mater Biol Appl. 2020 Jun:111:110750. doi: 10.1016/j.msec.2020.110750. Epub 2020 Feb 18.

Abstract

A promising direction for the replacement of expanded bone defects is the development of bioimplants based on synthetic biocompatible materials impregnated with growth factors that stimulate bone remodeling. Novel biomimetic highly porous ultra-high molecular weight polyethylene (UHMWPE)/40% hydroxyapatite (HA) scaffold for reconstructive surgery with the porosity of 85 ± 1% vol. and a diameter of pores in the range of 50-800 μm was developed. The manufacturing process allowed the formation of trabecular-like architecture without additional solvents and thermo-oxidative degradation. Biomimetic UHMWPE/HA scaffold was biocompatible and provided effective tissue ingrowth on a model of critical-sized cranial defects in mice. The combined use of UHMWPE/HA with Bone Morphogenetic Protein-2 (BMP-2) demonstrated intensive mineralized bone formation as early as 3 weeks after surgery. The addition of erythropoietin (EPO) significantly enhanced angiogenesis in newly formed tissues. The effect of EPO of bacterial origin on bone tissue defect healing was demonstrated for the first time. The developed biomimetic highly porous UHMWPE/HA scaffold can be used separately or in combination with rhBMP-2 and EPO for reconstructive surgery to solve the problems associated with difference between implant architecture and trabecular bone, low osteointegration and bioinertness.

Keywords: Hydroxyapatite; Microstructure; Protein; Scaffold; UHMWPE.

MeSH terms

  • Animals
  • Biocompatible Materials / chemistry*
  • Biocompatible Materials / pharmacology
  • Bone Diseases / surgery*
  • Bone Diseases / therapy
  • Bone Morphogenetic Protein 2 / chemistry*
  • Bone Morphogenetic Protein 2 / metabolism
  • Bone Morphogenetic Protein 2 / pharmacology
  • Bone Morphogenetic Protein 2 / therapeutic use
  • Bone Regeneration / drug effects
  • Bone and Bones / pathology
  • Bone and Bones / physiology
  • Drug Carriers / chemistry
  • Durapatite / chemistry*
  • Erythropoietin / chemistry*
  • Erythropoietin / metabolism
  • Erythropoietin / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred ICR
  • Nanocomposites / chemistry
  • Neovascularization, Physiologic / drug effects
  • Plastic Surgery Procedures
  • Polyethylenes / chemistry*
  • Porosity
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / metabolism
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Transforming Growth Factor beta / chemistry*
  • Transforming Growth Factor beta / metabolism
  • Transforming Growth Factor beta / pharmacology
  • Transforming Growth Factor beta / therapeutic use

Substances

  • Biocompatible Materials
  • Bone Morphogenetic Protein 2
  • Drug Carriers
  • Polyethylenes
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • recombinant human bone morphogenetic protein-2
  • ultra-high molecular weight polyethylene
  • Erythropoietin
  • Durapatite